



# SHIONOGI & CORP LTD.

ISIN: JP3347200002 WKN: 4507 Asset Class: Stock

<b>Company</b>	2024/04/26 08:00:00
	<b>Price</b>
	<b>7,306.00</b>
	JPY
<b>Difference</b>	 <b>2.21%(158.00)</b>



<b>Contact Details</b>	
SHIONOGI & CO. LTD.	Tel: +81-6-6202-2161
--	Fax: +81-6-6229-9596
3-1-8 Dosho-machi, Chuo-Ku	Web: <a href="http://www.shionogi.co.jp">http://www.shionogi.co.jp</a>
541-0045 Osaka	E-mail: -

## Company Profile

Shionogi & Co., Ltd. engages in the research, development, supply, manufacture and sale of pharmaceutical products. Its products include prescription drugs, over-the-counter drugs, diagnostic reagents, medical devices and others. The company was founded by Gisaburo Shiono on March 17, 1878 and is headquartered in Osaka, Japan.

## Financial figures, Fiscal year: from 01.04. to 31.03.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	784,192,000,000		659,205,000,000		556,238,000,000	
<b>Common stock capital</b>		21,279,000,000		21,279,000,000		21,279,000,000
<b>Fixed assets</b>	527,608,000,000		491,396,000,000		442,754,000,000	
<b>Equity capital of a company</b>		1,121,878,000,000		993,285,000,000		864,550,000,000
<b>Cash and cash equivalents</b>	309,224,000,000		254,420,000,000		276,173,000,000	
<b>Accrued liabilities</b>		12,867,000,000		15,412,000,000		16,318,000,000
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		158,552,000,000		124,396,000,000		100,180,000,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		30,106,000,000		32,656,000,000		33,976,000,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		4,926,000,000		5,708,000,000		5,301,000,000
<b>Total assets</b>	1,311,800,000,000	1,311,800,000,000	1,150,601,000,000	1,150,601,000,000	998,992,000,000	998,992,000,000

## Balance notes

	2023	2022	2021
<b>Accounting standard</b>	IFRS	IFRS	IFRS
<b>Employees</b>	5,680	5,693	5,485
<b>Equity ratio</b>	87.19%	87.86%	88.39%
<b>Debt-equity ratio</b>	14.70%	13.82%	13.14%

## Others

	2023	2022	2021
<b>Tax Expense Rate</b>	16.26%	10.16%	21.64%

## Income statement

	2023	2022	2021
<b>Turnover</b>	426,684,000,000	335,138,000,000	297,177,000,000
<b>Net income</b>	184,965,000,000	114,185,000,000	111,858,000,000
<b>EBIT</b>	1,294,386,000	758,100,000	856,812,000
<b>Operating income before taxes</b>	220,365,000,000	126,288,000,000	143,018,000,000
<b>Cash Flow</b>	177,867,000,000	102,068,000,000	109,039,000,000
<b>Net interest income</b>	4,634,000,000	-62,000,000	216,000,000
<b>Research and development expenses</b>	102,392,000,000	72,996,000,000	54,249,000,000
<b>Income taxes</b>	35,836,000,000	12,829,000,000	30,956,000,000
<b>Result from investments in subsidiaries, associates and other</b>	-33,000,000	-20,000,000	0
<b>Revenues per employee</b>	450,723	353,211	325,080

## Board of Directors

Fumi Takatsuki	Member of Supervisory Board
Hiroshi Ozaki	Member of Supervisory Board
Keiichi Ando	Member of Supervisory Board
Takuko Sawada	Member of Supervisory Board

## Members of Management Board

Ph.D. Isao Teshirogi	Chairman of Managing Board
John Keller	Member of Executive Committee
Kazuhiro Hatanaka	Member of Executive Committee
Kohji Hanasaki	Member of Executive Committee
Noriyuki Kishida	Member of Executive Committee
Ryuichi Kiyama	Member of Executive Committee
Toshinobu Iwasaki	Member of Executive Committee
Yasuyoshi Isou	Member of Executive Committee